clotting of whole plasma in a mean of 65 s. Macrophage procoagulant activity was at least partially independent of exogenous Factor VII as judged by a mean clotting time of 99 s in Factor VII-deficient plasma and by neutralization of procoagulant activity by an antibody to Factor VII. Immunoprecipitation of extracts of macrophages metabolically labeled with ['5Sjmethionine by Factor VII antibody and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed a labeled protein consistent in size with the known molecular weight of blood Factor VII, 48 ,000. The addition of 50 1Ag of unlabeled, purified Factor VII blocked recovery of the 48,000-mol wt prQtein. In addition, supernatants of cultured macrophages from six normal volunteers had Factor X-activating activity that was suppressed an average of 71% after culture in the presence of 50 tiM coumadin or entirely by the Factor VII antibody indicating that Factor VII synthesized by the cell was biologically active. Endotoxin in vitro induced increases in cellular tissue factor but had no consistent effect on macrophage Factor VII activity. We also examined the tissue factor and Factor VII activities of freshly lavaged alveolar cells from nine subjects with clinical and/or histologic evidence of sarcoidosis. Four of the nine subjects expressed increased tissue factor and seven of nine had increased Factor VII activity over the normal range (P < 0.01). We estimate the mean Factor VII associated with the cells of sarcoid patients to be 4.7 ng/10' cells (range 0. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] (1, 2) . Attenuation of the hypercellular characteristics of acute complex glomerulonephritis by antimacrophage antiserum (3) and by defibrinogenation (4) indicated a direct causal role for both the macrophage and fibrin in immunologically mediated tissue injury. Monocytes are induced to express procoagulant activity by T helper lymphocytes directly through cellular interaction after stimulation with endotoxin or immune complexes (5, 6) and indirectly by elaboration of lymphokines in response to mitogens, antigens or allogeneic stimulation (7) (8) (9) (10) . Studies on experimental animals indicate that macrophages at sites of inflammation express procoagulant activity, respond to similar signals as do monocytes, and show a correlation between their activation state and the amount of procoagulant activity (1 1).
Initiation of coagulation by human monocytes/macrophages occurs with the expression of tissue factor, the lipophilic protein cofactor required for the extrinsic coagulation pathway (12, 13) . Factor VII binds to this cofactor in the presence of calcium to form a proteolytically active complex with the capacity to activate Factors IX and X (14-17). Previous reports suggested that thioglycollate-elicited mouse peritoneal macrophages express a Factor VII-like activity, but these reports did not unequivocally identify this protease (18) (19) (20) Fibrin is conspicuous in a number of inflammatory processes involving the lung. Histologic studies show fibrin both in the interstitium and along the alveolar surfaces during the cellular phase of idiopathic pulmonary fibrosis (22) . Fibrin is prominent along the alveolar ducts during the exudative phase of the adult respiratory distress syndrome (23) . Because pulmonary macrophages are also prominent in the histopathology of these disorders, we examined the procoagulant activity of human alveolar macrophages in vitro. In this report we describe the synthesis and expression of Factor VII and tissue factor by these cells. Further, we investigate alveolar macrophage procoagulant activity in a group of patients with an inflammatory lung disease in which macrophages are known to be prominent, sarcoidosis (24).
Methods
Bronchoalveolar lavage and cell preparation. 13 healthy community volunteers underwent fiberoptic bronchoscopy as previously described (25) . Differential counting of lavaged cells from these subjects showed mean percentages of macrophages, lymphocytes, and neutrophils to be 96, 3, and 1%, respectively. Nine patients with suspected or confirmed diagnosis of pulmonary sarcoidosis also underwent bronchoscopy after informed consent. In eight individuals, the diagnosis was established on histologic evidence of noncaseating granulomata and compatible clinical and radiographic findings. In one subject, the diagnosis was based on clinical criteria alone (26) . The Broze and Majerus (27) as modified by Fair (28) . Factor X was purified according to Fair and colleagues (29) . Thromboplastin (Simplastin) and brain cephalin were obtained from General Diagnostics (Morris Plains, NJ) and stored in dry form at 4VC. Ficoll-Hypaque and Percoll were obtained from Pharmacia Fine Chemicals (Piscataway, NJ). All other reagents were of highest grade commercially available. The media and sera used in these experiments were free of endotoxin contamination as judged by a limulus amoebocyte assay that detects I ng/ml of endotoxin (30) .
Procoagulant assays. Intact macrophages were assayed for procoagulant activity by a modified one-stage prothrombin time (5 Intact cell procoagulant activity in the Factor VII-deficient plasma was also tested for its susceptibility to neutralization by a previously described polyclonal Factor VII antibody (28) . For these experiments, 5 X 101 macrophages were suspended in 75 Ml of MEM and mixed with either 25 Al of normal rabbit IgG (1 mg/ml) or rabbit IgG that contained Factor VII antibodies (1 mg/ml) for 30 min at 370C. The cells were then washed once and resuspended in 100 Ml of MEM for procoagulant assays in Factor VII-deficient plasma as described above.
Cell-dependent procoagulant activity in the Factor VII assays was further analyzed to access the relative contributions of tissue factor alone and Factor VII associated with cellular tissue factor. To do this, we first established the quantitative relationship between dilutions of normal human plasma (as a source of Factor VII) and clotting time (seconds) in Factor VII-deficient plasma for various concentrations of rabbit brain thromboplastin (0.1, 0.3, 0.6, 0.9, 2.2, 6, and 10 mg/ml) in a log-log plot. This consisted of a family of straight lines progressively closer as the concentration of thromboplastin increased. The concentration of Factor VII in the plasma standard as determined by radioimmunoassay was 337 ng/ml (28) . The observed clotting times of the cells in Factor VII-deficient plasma were then plotted on the appropriate straight line for the thromboplastin equivalent determined for the same cells in whole plasma. We then expressed the Factor VII activity of alveolar macrophages as nanogram equivalents to the plasma standard per 106 cells. In this way, cell-associated Factor VII activity could be separated from the effect of cellular tissue factor binding to any residual Factor VII in the genetically deficient plasma.
Factor X-activating assay. The ability of lysates or cell-free culture supernates of alveolar macrophages to directly activate purified Factor X was assessed by fluorometry. Assays were performed by modifications of the procedure described by Shands (19) . Alveolar macrophages (3.5 X 106) were made adherent to 35-mm petri dishes, incubated 2 h at 370C in 10% fetal bovine serum, washed, and then incubated overnight in 2 ml of serum-free MEM with or without 50 MM coumadin. Preliminary experiments indicated that coumadin had an inconsistent effect on lysate activity unless nascent Factor X-activating activity was at least partially removed. Therefore, before overnight culture in MEM, all cells were incubated in 10 Mg/ml of trypsin for 30 min at 37°C followed by neutralization in soybean trypsin inhibitor, 400 Mglml, for 10 min at 37°C. Neither the trypsin nor the coumadin (up to 100 MM) were toxic to macrophages as judged by morphology and trypan blue exclusion. After overnight culture, the cell-free supernates were made 0.05% in Triton X-100, dialyzed against water, and concentrated 10-fold by lyophilization. The cells were then scraped from the wells and subjected to freeze-thawing and then to four 1-s pulse sonications. The supernatants reconstituted in MEM were made 0.5 mg/ml in brain thromboplastin and assayed for Factor X-activating activity in a reaction mixture consisting of 100 Ml of supernatants, 90 Ml of 10 mM Tris-HCl pH 7.8, 100 Ml of brain cephalin, 10 Ml of 0.25 M CaCl2, 10 Mg of purified Factor X, and a final concentration of 0.1 mM benzoxycarbonyl -isoleucine -glutamine -glycine -arginine -aminomethyl-coumarinamide (Peninsula Laboratories, San Carlos, CA). The mixture was incubated for 45 min at 37°C, the reaction stopped with 10 Ml of 1 mM p-nitrophenylguanidinobenzoate, the solution clarified by centrifugation, and fluorescence recorded in a Perkin-Elmer 650-I1S spectrofluorometer (Perkin-Elmer Corp., Norwalk, CT). Fluorescence measured in the same reaction mixture containing brain thromHuman Macrophage Procoagulant Activity boplastin, 0.5 mg/ml, in MEM with 0.5% Triton instead of the reconstituted supernatants, was subtracted from the experimental values. All reactions were done in duplicate. Preliminary data showed the fluorescence to be proportional to purified Factor Xa from 0.5-2 ug in the 45-min assay. Also, the supernatants did not appreciably hydrolyze the Factor Xa substrate in the absence of either added Factor X or brain thromboplastin. Data is expressed as mean picomoles of substrate hydrolyzed in duplicate determinations by standardization of fluorescence with known concentrations of purified product (aminomethylcoumarin). Cell lysates were assayed identically to supernatants except that thromboplastin was omitted and the reaction was stopped after 15 min at 370C.
Metabolic labeling, immunoprecipitation, and autoradiography. Labeling, immunoprecipitation, and autoradiography were carried out as previously described (25) . Briefly, 107 alveolar macrophages/25-cm2 flask were labeled in MEM containing 0.5% fetal bovine serum, 10% stock methionine, and [35S]methionine, 100 ttCi/ml, for 18 h at 370C.
The cell monolayers were then washed, scraped, and homogenized in 3 ml of Tris buffer (pH 7.4) containing 5 mM EDTA. Membrane and cytosol fractions of the cell were prepared by ultracentrifugation at 100,000 g for 90 min. Immunoprecipitation was done after clarification with Staph A to minimize nonspecific precipitation. The reaction medium consisted of 100 Ml of a cellular membrane fraction or the cytosol fraction solubilized in homogenizing buffer containing 0.1% SDS and 0.5% Triton X-100. All samples contained 100 U/ml Trasylol and 0.1 mM phenylmethylsulfonyl fluoride. After 2 h of incubation at room temperature with 15 Ml of immune IgG (Factor VII antibody) or control rabbit IgG, the complexes were isolated by Staph A binding, washed, and eluted by boiling in sample buffer for SDS-gel electrophoresis (31). After electrophoresis under reduced conditions in 10% acrylamide slab gels, the gels were dried and autoradiographed for 10-14 d at -700C.
Results
Procoagulant activity of human alveolar macrophages. Intact macrophages from each of 13 healthy volunteers promoted fibrin formation in a one-stage prothrombin assay using pooled human plasma as a source of coagulation factors (Fig. 1) . The mean clotting time and one standard deviation, for the group was 65±14 s. This clotting time is equivalent to 480 U thromboplastic activity (1 mg/ml = 1,000 U). 6 of the 13 volunteers smoked at least 1 pack/d; the remaining subjects were nonsmokers. There was no difference in procoagulant activity between these subgroups.
We first investigated the chemical nature of this procoagulant activity. Preliminary studies with five individuals demonstrated that all procoagulant activity required exogenous Factor X (not shown). Previous reports indicated that stimulated murine peritoneal (18) (19) (20) and rabbit alveolar (32) the studies in mice suggested a partial involvement of Factor VII-like activity. We thus tested the ability of human macrophages to clot plasma genetically deficient in Factor VII. We observed a mean clotting time of 99±22 s (Fig. 1) . In paired samples of cells assayed in both plasmas, the clotting times were consistently longer in the Factor VII-deficient plasma than whole plasma (not shown). The total procoagulant activity is not explained simply as tissue factor activity as incubation of Factor VII-deficient plasma with 480 U of thromboplastin gave a clotting time of only 150 s. These findings suggest that the human cells express a procoagulant in addition to thromboplastin.
To test the possibility that freshly lavaged macrophages express Factor VII, we determined whether a neutralizing antibody prepared against purified Factor VII would block the procoagulant activity. Control experiments with nonimmune IgG showed no prolongation of macrophage associated procoagulant activity assayed in Factor VII-deficient plasma (Fig.  2) is largely or entirely due to the extrinsic pathway of initiation of the coagulation cascade. These experiments do not, however, determine the source of the Factor VII activity. Alveolar macrophages may be stimulated to express thromboplastin activity and then bind blood-derived Factor VII as reported for human monocytes by Broze (17) . We examined the alternative possibility that macrophages may synthesize Factor VII as suggested by Tsao et al. (21) . We metabolically labeled macrophages for 18 h with [35Slmethionine, prepared cytosol and membrane fractions of the labeled cells, immunoprecipitated the cellular fractions with nonimmune IgG or IgG that contained Factor VII antibody, and analyzed the precipitates by SDS-polyacrylamide gel electrophoresis. Fig. 3 A illustrates a typical autoradiograph of the immunoprecipitates of the cytosol fraction of the cell. The major labeled protein precipitated by the Factor VII antibody was 48,000±2,000 mol wt and corresponded closely with the known molecular weight of human Factor VII (27, 28, 33) . In addition, there were four to five faint bands between 45,000 and 150,000 mol wt. To further confirm the specificity of this immunoprecipitate, we used unlabeled purified Factor VII to compete with the labeled protein for the antibody (Fig. 3 B) . Addition of 50 Ag of Factor VII to the labeled cytosol fraction before the precipitation step totally blocked recovery of the labeled 48,000-mol wt protein.
There was also partial loss of the high molecular band (-150 (19) . The cellassociated Factor X-activator activity increased in response to endotoxin in vitro. These observations indicate rodent macrophages may contain the y-carboxylase necessary to activate Factor VII. We tested whether human alveolar macrophages released active Factor VII that was coumadin sensitive. If so, this would imply the cells can synthesize biologically active Factor VII inasmuch as coumadin has no direct inhibitory effect in the procoagulant assay. In these experiments we assayed Factor VII activity by a one-stage Factor X-activator assay using a fluorescent oligopeptide specific for Factor Xa. Data in Table I show the results of experiments with cell-free supernatants from cultured macrophages of six separate normal volunteers. In each case, Factor X-activating activity was observed in the concentrated cell-conditioned media. However, as shown by the representative result with subject 6, expression of activity required the addition of brain thromboplastin to the supernatants. This finding correlated with our observation that no procoagulant activity was measurable in the nascent supernatants (not shown). That the cultured cells' release of Factor X-activating activity represented secretion of Factor VII was indicated by the fact that in two cases tested 25 Al of the Factor VII antibody completely blocked Factor X-activating activity (not shown). In every case, the addition of 50 UM coumadin to the start of the cultures at least partially blocked the subsequent recovery of Factor X-activating activity (Table  I ). The mean percent inhibition by coumadin was 71% (range 23-100%).
In additional experiments, we tested the lysates of cultured cells for the Factor X activator. We observed coumadin to have a small and inconsistent effect on human alveolar macrophage Factor X-activator activity after 18-20 h culture in vitro. However, by removing much of the nascent activity with a 30-min exposure to trypsin (10 Mg/ml) a consistent coumadin effect could be observed on the Factor X-activator activity of these cultured cells. Trypsin removed an average of 55% of the initial Factor X-activator activity (range 30-86%). Subsequent culture of the cells in 50 uM coumadin suppressed Factor X-activator activity by an average of -25% compared with that of cells cultured without coumadin. In contrast, coumadin had no measurable effect on cellular tissue factor activity when tested in a standard one-stage prothrombin assay identically to that described in Fig. 1 . These data indicate that at least some-and possibly all-of the Factor VII antigen synthesized by human alveolar macrophages is biologically active.
Effect of endotoxin on human alveolar macrophage Factor VII activity in vitro. A number of investigators have shown that freshly isolated human monocytes from peripheral blood have little or no procoagulant activity. These cells, in collaboration with lymphocytes, generate substantial procoagulant activity upon stimulation with endotoxin in vitro (5, 34) . We examined whether alveolar macrophages would also respond to endotoxin in vitro. Lavaged cells from seven volunteers were cultured overnight in MEM containing 5% heat-inactivated human serum or in this medium supplemented with 1 Mg/ml of endotoxin. After 18 h, the cells were washed three times and assayed for procoagulant activity in Factor VII-deficient plasma. In four cases the cells were also assayed in whole plasma. Data in Table II show results expressed as mean±1 SD of the clotting times as well as in units of thromboplastin or Factor VII activity. In each of the four subjects' cells tested in whole plasma, endotoxin increased procoagulant activity. The thromboplastic activity increased from a mean of 85 U to a mean of 290 U in response to endotoxin. However, when alveolar macrophages were assayed in Factor VII-deficient plasma, no significant difference could be observed between the endotoxin-treated and untreated cultures in Factor VII activity (Table II) . Further, no trend in the Factor VII activity was evident as two of seven individuals showed an increase in their clotting times after incubation with endotoxin (not shown).
Factor VII activity of lavaged cells from patients with sarcoidosis. Previously reported data indicate that the alveoli of patients with sarcoidosis contain increased numbers of both macrophages and lymphocytes (24) . We measured the procoagulant activity of freshly lavaged cells from nine such subjects in whole and Factor VII-deficient plasmas. Assays were performed without further purification of macrophages, because preliminary experiments indicated that gradient centrifugation (Percoll) resulted in some loss of activity and a cellular adherence step precluded comparison with the control group. Moreover, all evidence to date indicates that lymphocytes, the only cell contaminating these preparations, do not express procoagulant activity (7, 35, 36) . i.e., one chain versus the more active two-chain enzyme. As a group, the increases in both tissue factor and Factor VII were statistically significant. In three of these nine patients, we measured procoagulant activity in Factor X-deficient plasma. In each case, there was no activity in the absence of exogenous Factor X.
We considered whether there was a relationship between observed procoagulant activity and clinical characteristics of the patient group. As the data in Table III show, all but two of the individuals had 20-50% lymphocytes in the lavage preparations. However, the percentage of lymphocytes did not correlate with the procoagulant activities at least within this small population.
Discussion
Previous observations in humans indicate that upon appropriate stimulation monocytes initiate coagulation via the extrinsic pathway by expression of tissue factor (7, 11, 17, 36 (Fig. 1) .
The role of Factor VII activity in the biology of pulmonary macrophages is unclear. Fibrinogen is undetectable in lavaged alveolar fluid, and fibrin is not normally found in extravascular lung tissue (38). The procoagulant activity of these cells may simply reflect a programmed response to cellular stimulation, inasmuch as alveolar macrophages are exposed continuously to the environment and a variety of inducers. Factor VII could also serve a role in normal lung physiology. Although we have not tested whether thrombin formation occurs in vivo, the generation of thrombin in a fibrinogen-free environment would allow the expression of previously reported functions of thrombin in addition to clot formation. For example, thrombin is chemotactic for monocytes and stimulates lung fibroblasts to elaborate arachidonic acid metabolites (39, 40) . These processes offer possible mechanisms for continued influx of young macrophages onto the alveolar surfaces.
Fibrin is a conspicuous part of acute and chronic inflammatory disorders of the lung. A number of pathways, in addition to macrophages, could initiate fibrin deposition after the leakage of plasma constituents into the interstitial and alveolar compartments of the lung. Strong but circumstantial evidence suggests that such tissue fibrin may not only be a marker of injury but also exert an influence on the course of healing. Astrup has reviewed evidence that fibrin deposition and the rate of its resorption regulate the events in scar formation, particularly fibroblast proliferation (41) . Fibroblasts utilize fibrin and fibronectin substrata as a matrix for proliferation and collagen deposition (42) . Moreover, Spencer and Pratt in separate pathologic studies have noted the correlation between persistent fibrin deposits and subsequent localization of fibrotic processes in the lung (23, 24) . Our observations with alveolar macrophages may be germane, because we have previously shown that normal human alveolar macrophages synthesize and express a plasminogen activator (25) . Macrophages thus synthesize the rate-limiting enzymes in proteolytic cascades initiating both fibrin deposition (Factor VII-tissue factor) and resorption (plasminogen activator). These cells are in a position then to influence fibrin turnover in the lung. By coordinating fibrin turnover with the elaboration of other factors important to scar formation, e.g., fibronectin and fibroblast growth factor, lung macrophages may well modulate healing.
We report here our initial findings in a group of patients with sarcoidosis, a chronic inflammatory disease that may result in pulmonary fibrosis (43) . We observed increased Factor VII activity in seven of nine subjects (Table III) . Because the Factor VII activity of monocytes is induced by T-helper lymphocytes (21) , the increase in alveolar macrophage associated Factor VII activity in sarcoid patients may be due to the disproportionate increase in alveolar T helper cells known to occur in these individuals (24). Based on these observations, we retrospectively examined biopsy specimens from five sarcoid patients for evidence oftissue fibrin deposition. We observed fibrin in the central, macrophage-rich areas of sarcoid granulomata by immunoperoxidase stains of lung or lymph node biopsy specimens from three of five subjects. The peripheral areas rich in fibroblasts and collagen were negative (Elizabeth Hammond and Harold Chapman, unpublished observations). These findings support the hypothesis that fibrin deposition may precede and support subsequent scar formation in sarcoidosis. Whether the observed increased macrophage Factor VII activity is related to the observed tissue fibrin and whether the Factor VII activity and/or tissue fibrin is actually linked to the course of the disease requires further study.
